ArticleFrontiers in immunology2025
Integration of single-cell and bulk RNA-seq via machine learning to reveal ferroptosis- and lipid metabolism-driven immune landscape heterogeneity and predict immunotherapy response in colon cancer.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study explored the interactions between ferroptosis and lipid metabolism in colon cancer, established a prognostic model to elucidate immune microenvironment heterogeneity, and evaluated the prospects of immunotherapy. Methods: Transcriptome sequencing and single-cell transcriptome data from The Cancer Genome Atlas and Gene Expression Omnibus were analyzed. Nonnegative matrix factorization clustering and weighted gene coexpression network analysis identified ferroptosis- and lipid metabolism-related genes. Machine learning algorithms including support vector machine, random forest, extreme gradient boosting, and least absolute shrinkage and selection operator regression were used to construct a prognostic model. Expression patterns of selected genes were validated via Human Protein Atlas and immunohistochemistry. Results: We developed a prognostic risk model comprising 13 genes through the application of multiple machine learning algorithm sand and confirmed as an independent prognostic factor. Gene set enrichment analysis (GSEA) revealed that the high-risk group was significantly enriched in hypoxia, tumor angiogenesis, epithelial-mesenchymal transition (EMT), and extracellular matrix (ECM) component synthesis and interactions, suggesting enhanced invasiveness and metastatic potential. Conversely, the low-risk group was enriched in biological processes related to oxidation, lipid metabolism, and ferroptosis. Moreover, the high-risk group exhibited more pronounced stromal infiltration and immunosuppressive activity within the tumor microenvironment, suggesting a greater tendency toward immune escape. In contrast, the low-risk group showed better responses to immunotherapy, a finding validated across multiple real-world immunotherapy datasets. Additionally, cell-cell communication analysis based on single-cell datasets revealed that M2 macrophages might be associated with T-cell exhaustion through SPP1-CD44 ligand-receptor interactions, thereby exerting immunosuppressive effects. Finally, immunohistochemistry (IHC) experiments confirmed the differential expression patterns of the SHH, WDR72, and EPOP genes between tumor and normal tissues, corroborating our findings at the mRNA level. Conclusion: In this study, we conducted a comprehensive analysis of ferroptosis-lipid metabolism interactions in colon cancer by integrating bulk transcriptomic and single-cell RNA sequencing data. The prognostic model constructed on the basis of lipid metabolism and ferroptosis-related genes has potential as an independent prognostic biomarker for colon cancer patients and may serve as a predictor of immunotherapy response, facilitating the optimization of personalized therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.